We are live on ! Find out more
SAM

Simplify Asset Management Portfolio holdings

AUM $7.19B
1-Year Est. Return 6.88%
This Fund
S&P 500
This Quarter Est. Return
+3.5%
1 Year Est. Return
+6.88%
3 Year Est. Return
+44.98%
5 Year Est. Return
+50.08%
10 Year Est. Return
AUM
$7.19B
AUM Growth
+$670M
Cap. Flow
+$523M
Cap. Flow %
7.27%
Top 10 Hldgs %
91.65%
Holding
163
New
20
Increased
70
Reduced
37
Closed
22

Sector Composition

Rank Sector Weight
1 Healthcare 5.05%
2 Energy 0.44%
3 Industrials 0.38%
4 Technology 0.22%
5 Real Estate 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LITL
51
Simplify Piper Sandler US Small-Cap PLUS Income ETF
LITL
$6.87M
$3.15M 0.04%
91,464
ISRG icon
52
Intuitive Surgical
ISRG
$122B
$2.98M 0.04%
7,492
-3,275
-30% -$1.43M
XXV
53
Simplify Ancorato Target 25 Distribution ETF
XXV
$47.9M
$2.76M 0.04%
116,500
-8,500
-7% -$201K
PHAT icon
54
Phathom Pharmaceuticals
PHAT
$873M
$2.7M 0.04%
249,267
-13,119
-5% -$150K
CTAP
55
Simplify US Equity PLUS Managed Futures Strategy ETF
CTAP
$171M
$2.64M 0.04%
100,000
CORT icon
56
Corcept Therapeutics
CORT
$9.72B
$2.3M 0.03%
26,434
-11,329
-30% -$684K
QQQ icon
57
CALL
Invesco QQQ Trust
QQQ
$466B
$2.21M 0.03%
+3,000
New +$2.06M
ABEO icon
58
Abeona Therapeutics
ABEO
$399M
$2.13M 0.03%
345,416
-162,572
-32% -$893K
PCRX icon
59
Pacira BioSciences
PCRX
$1.01B
$2.11M 0.03%
83,083
+20,430
+33% +$483K
CSCO icon
60
Cisco
CSCO
$441B
$1.99M 0.03%
16,904
-2,955
-15% -$309K
CLDX icon
61
Celldex Therapeutics
CLDX
$2.77B
$1.98M 0.03%
53,134
-15,860
-23% -$512K
WMT icon
62
Walmart Inc
WMT
$909B
$1.91M 0.03%
16,890
+2,673
+19% +$332K
ABT icon
63
Abbott
ABT
$175B
$1.86M 0.03%
20,546
+5,040
+33% +$460K
DX
64
Dynex Capital
DX
$2.87B
$1.76M 0.02%
134,500
+52,921
+65% +$696K
EW icon
65
Edwards Lifesciences
EW
$49.4B
$1.69M 0.02%
18,668
+4,590
+33% +$385K
KYTX icon
66
Kyverna Therapeutics
KYTX
$453M
$1.63M 0.02%
182,603
+9,497
+5% +$84.3K
MFA
67
MFA Financial
MFA
$960M
$1.63M 0.02%
167,746
-41,254
-20% -$400K
CMPS
68
Compass Pathways
CMPS
$1.67B
$1.62M 0.02%
114,281
-44,771
-28% -$454K
NLY icon
69
Annaly Capital Management
NLY
$16.9B
$1.61M 0.02%
71,839
+22,436
+45% +$495K
INSM icon
70
Insmed
INSM
$23.5B
$1.51M 0.02%
14,190
+3,407
+32% +$413K
IBM icon
71
IBM
IBM
$200B
$1.41M 0.02%
5,014
+224
+5% +$56.4K
PLTR icon
72
Palantir
PLTR
$317B
$1.4M 0.02%
12,021
+317
+3% +$43.2K
LONA
73
LeonaBio Inc
LONA
$67.8M
$1.37M 0.02%
149,279
DELL icon
74
Dell
DELL
$256B
$1.37M 0.02%
3,172
+99
+3% +$28.6K
BRK.B icon
75
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.33M 0.02%
2,662
+40
+2% +$19.2K

Similar funds

Simplify Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Simplify Asset Management held 163 positions worth $7.19B, up 10% from $6.52B the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Simplify Asset Management deployed $523M of net new capital in Q2 2026, opening 20 new positions and adding to 70 existing holdings. Its largest new stake was Simplify China A Shares PLUS Income ETF: 428,078 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 5% of assets, up from 3.7% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $36.1M trimmed.

  • Simplify Asset Management's largest Q2 2026 buy was Simplify China A Shares PLUS Income ETF: 428,078 shares worth $12.4M.
  • Simplify Asset Management added most to Simplify Government Money Market ETF in Q2 2026, an estimated $311M increase.
  • Simplify Asset Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $36.1M.
  • Simplify Asset Management fully exited Regeneron Pharmaceuticals in Q2 2026, selling an estimated $8.42M.
  • Simplify Asset Management's ten largest holdings make up 92% of its $7.19B portfolio in Q2 2026.
  • Simplify Asset Management opened 20 new positions and closed 22 in Q2 2026.
  • Simplify Asset Management's portfolio value rose 10% quarter-over-quarter to $7.19B.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.